David Scott Arrington

David Scott Arrington possesses extensive experience in investor relations and corporate communications, currently serving as the Former SVP of Investor Relations & Corporate Affairs at REVOLUTION Medicines since March 2022. Prior roles include VP positions at Freeline, Coherus BioSciences, Achaogen, and serving as Chief Marketing Officer at Stanford University School of Medicine. Arrington also held significant roles at UCSF, Elan Pharmaceuticals, Genentech, and Bristol-Myers Squibb, showcasing a strong background in corporate communications and relations across various leading organizations. David Scott Arrington earned a Bachelor of Arts, Cum Laude, from Washington State University and has further education from the University of Wales Trinity Saint David.